Bavarian Nordic A/S (BVNRY) Stock Analysis

Bavarian Nordic A/S (BVNRY) Healthcare & Pipeline Overview

Bavarian Nordic A/S is a commercial-stage biotechnology company focused on developing and commercializing vaccines for infectious diseases and cancer. With a diverse portfolio of approved vaccines and a pipeline of candidates in clinical trials, the company addresses critical unmet needs in global public health and oncology, operating across multiple international markets.

What Is the Investment Thesis for BVNRY?

The company's revenue is supported by government contracts for smallpox and monkeypox vaccines, providing a stable base for future growth. The ongoing Phase III trials for MVA-BN RSV represent a significant catalyst, targeting a large market with substantial unmet needs. With a P/E ratio of 10.33 and a profit margin of 22.2%, the company demonstrates financial stability and profitability. However, investors may want to evaluate the risks associated with clinical trial outcomes and regulatory approvals, which could impact future revenue streams. The company's beta of 1.09 indicates market correlation.

Based on FMP financials and quantitative analysis

BVNRY Key Highlights

Market capitalization of $2.43B reflects investor confidence in Bavarian Nordic's vaccine portfolio and pipeline.

• P/E ratio of 10.33 suggests the company is undervalued compared to its earnings.
• Profit margin of 22.2% indicates strong profitability and efficient operations.
• Gross margin of 48.5% demonstrates the company's ability to maintain competitive pricing and manage production costs.
• The company's diverse vaccine portfolio, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines, provides multiple revenue streams and reduces reliance on a single product.

Who Are BVNRY's Competitors?

BVNRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BVNRY's Key Strengths?

Established portfolio of approved vaccines.

• Proprietary MVA-BN vaccine platform.
• Strong relationships with governments and public health organizations.
• Experienced management team.

What Are BVNRY's Weaknesses?

Reliance on government contracts for revenue.

• Competition from larger pharmaceutical companies.
• Dependence on successful clinical trial outcomes.
• Limited geographic presence in some markets.

What Could Drive BVNRY Stock Higher?

Phase III clinical trial results for MVA-BN RSV vaccine expected in late 2026.

• Government contracts for smallpox and monkeypox vaccines provide a stable revenue stream.
• Development of new vaccines for emerging infectious diseases.
• Potential regulatory approvals for ABNCoV2 vaccine for SARS-CoV-2 in 2027.
• Expansion into new geographic markets.

What Are the Key Risks for BVNRY?

Clinical trial failures could negatively impact the company's pipeline and future revenue.

• Regulatory delays or rejections could delay the commercialization of new vaccines.
• Competition from larger pharmaceutical companies could erode market share.
• Changes in government funding priorities could reduce revenue from government contracts.
• Currency fluctuations could impact the value of the company's international sales.

What Are the Growth Opportunities for BVNRY?

• MVA-BN RSV Vaccine: The MVA-BN RSV vaccine, currently in Phase III clinical trials, represents a significant growth opportunity for Bavarian Nordic. Respiratory syncytial virus (RSV) affects millions of people annually, particularly infants and the elderly, creating a substantial market for an effective vaccine. Successful completion of Phase III trials and subsequent regulatory approval could generate significant revenue streams, potentially reaching hundreds of millions of dollars annually, within the next 2-3 years. Bavarian Nordic's competitive advantage lies in its MVA-BN platform, which has demonstrated safety and efficacy in previous clinical trials.
• ABNCoV2 Vaccine: The ABNCoV2 vaccine, which has completed Phase II clinical trials for the treatment of SARS-CoV-2, offers a growth opportunity in the evolving market for COVID-19 vaccines. While the initial demand for COVID-19 vaccines has decreased, there remains a need for booster shots and vaccines that address emerging variants. If approved, ABNCoV2 could capture a share of this market, generating revenue in the tens of millions of dollars. The timeline for potential commercialization is dependent on further clinical trials and regulatory approvals, potentially within the next 1-2 years.
• TAEK-VAC Cancer Vaccine: The TAEK-VAC cancer vaccine, currently in Phase I/II clinical trials for the treatment of advanced HER2 and brachyury-expressing cancers, represents a long-term growth opportunity for Bavarian Nordic. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine. Successful development and commercialization of TAEK-VAC could generate significant revenue, although the timeline is uncertain due to the early stage of clinical development. The potential market size could reach hundreds of millions of dollars annually, but commercialization is likely several years away.
• Geographic Expansion: Bavarian Nordic has the opportunity to expand its geographic presence, particularly in emerging markets where access to vaccines is limited. By partnering with local distributors and governments, the company can increase its sales and market share in these regions. This expansion could generate incremental revenue growth of 5-10% annually over the next 3-5 years. The company's existing infrastructure and expertise in vaccine development and manufacturing provide a competitive advantage in entering new markets.
• Government Contracts: Bavarian Nordic has a history of securing government contracts for its vaccines, particularly for smallpox and monkeypox. These contracts provide a stable revenue stream and support the company's research and development efforts. The company can continue to pursue government contracts for its existing vaccines and new vaccine candidates, ensuring a consistent source of funding and market access. The value of these contracts can range from tens to hundreds of millions of dollars annually, depending on the specific vaccine and the government's needs. Ongoing government preparedness initiatives for emerging infectious diseases will likely continue to drive demand.

What Opportunities Does BVNRY Have?

• Expansion into emerging markets.
• Development of new vaccines for unmet medical needs.
• Strategic partnerships and collaborations.
• Increased government funding for vaccine research and development.

What Are BVNRY's Competitive Advantages?

• Proprietary Vaccine Technology: Bavarian Nordic's MVA-BN platform provides a competitive advantage in developing safe and effective vaccines.
• Regulatory Expertise: The company has a strong track record of obtaining regulatory approvals for its vaccines.
• Government Relationships: Bavarian Nordic has established relationships with governments and public health organizations.
• Manufacturing Capabilities: The company has specialized manufacturing facilities for vaccine production.

What Does BVNRY Do?

Bavarian Nordic A/S, founded in 1992 and headquartered in Hellerup, Denmark, is a biotechnology company dedicated to developing, manufacturing, and commercializing life-saving vaccines. The company's initial focus was on cancer vaccines, but it has since expanded to address infectious diseases. Bavarian Nordic's portfolio includes commercially available vaccines such as IMVAMUNE/IMVANEX/JYNNEOS for smallpox and monkeypox, Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, and MVABEA for Ebola. These vaccines are distributed across the United States, Europe, and other international markets. The company is actively developing new vaccines, including MVA-BN RSV for respiratory syncytial virus, ABNCoV2 for SARS-CoV-2, and TAEK-VAC for advanced HER2 and brachyury-expressing cancers. Bavarian Nordic operates through strategic partnerships and collaborations, including license agreements with the National Cancer Institute and Public Health Service, to enhance its research and development efforts. The company's mission is to improve global health by providing innovative vaccines to prevent and treat life-threatening diseases.

What Products and Services Does BVNRY Offer?

• Develops and manufactures vaccines for infectious diseases.
• Commercializes vaccines for smallpox and monkeypox under the names IMVAMUNE, IMVANEX, and JYNNEOS.
• Offers rabies vaccine for human use under the name Rabipur/RabAvert.
• Provides tick-borne encephalitis vaccine under the name Encepur.
• Manufactures Ebola vaccine under the name MVABEA.
• Conducts clinical trials for vaccines targeting respiratory syncytial virus (RSV), SARS-CoV-2, and certain cancers.
• Partners with organizations like the National Cancer Institute and Public Health Service for research and development.

How Does BVNRY Make Money?

• Develops and manufactures vaccines.
• Sells vaccines to governments and healthcare providers.
• Generates revenue through commercial sales of approved vaccines.
• Receives funding through government contracts and grants.
• Out-licenses vaccine technology and collaborates with other companies.

What Industry Does BVNRY Operate In?

Bavarian Nordic operates within the global biotechnology industry, which is characterized by intense research and development, regulatory scrutiny, and high growth potential. The market for vaccines is expanding due to increasing awareness of preventative healthcare and government initiatives to combat infectious diseases. The company competes with established pharmaceutical giants and specialized biotechnology firms. Bavarian Nordic's focus on developing and commercializing vaccines for both common and rare diseases positions it as a key player in the global vaccine market.

Who Are BVNRY's Key Customers?

• Governments: Purchase vaccines for national stockpiles and public health programs.
• Healthcare Providers: Administer vaccines to patients in hospitals and clinics.
• International Organizations: Procure vaccines for global health initiatives.
• Military Organizations: Acquire vaccines to protect personnel from infectious diseases.

Bavarian Nordic A/S has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 7.4% above estimates on average.

Quarterly Financial Performance: Bavarian Nordic A/S

Revenue for Bavarian Nordic A/S came in at $320.7M during Q2 FY2026, a 91.9% improvement versus the preceding quarter. The company recorded net income of $115.5M, with diluted EPS of $0.51. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, BVNRY averaged $0.26 in diluted EPS.

BVNRY Valuation & Market Position

With a $2.43B market cap, Bavarian Nordic A/S sits in the mid-cap segment of the market.

Return on equity for Bavarian Nordic A/S stands at 9.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.3%, showing how much profit it generates from its asset base. BVNRY trades at a trailing price-to-earnings ratio of 10.33, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 9.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.3%, the inverse of the P/E and a quick read on earnings relative to price.

Bavarian Nordic A/S's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.67 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Bavarian Nordic A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hellerup, DK. The company is led by CEO Paul John Chaplin. BVNRY has traded publicly since 2013.

BVNRY Financials

BVNRY Latest News

BVNRY Analyst Consensus

BVNRY MoonshotScore

Bavarian Nordic A/S Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources